Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%

Dublin, Nov. 16, 2017 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market (4th Edition) 2017-2030" report has been added to Research and Markets' offering.

The Antibody Drug Conjugates Market (4th Edition), 2017-2030' report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, both small and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 10% of candidate therapies are presently in advanced stages (phase II and above); we anticipate the market to witness continued growth in the next 5-10 years.

Since the first approval of MYLOTARG in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS in 2011 and KADCYLA in 2013, there was a temporary, but evident, decline in the popularity of ADCs.

This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA and re-approval of MYLOTARG has renewed the interest of stakeholders in the domain. This growing popularity and potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 1,395 patents in 2009 to 10,208 patents in the first half of 2017.

While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies. In addition, the ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of ADCs that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.


Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Key Opinion Leaders

6. Key Therapeutic Areas

7. Company And Drug Profiles

8. Partnerships And Collaborations

9. Venture Funding

10. Academic Grants

11. Combination Therapies

12. Novel Conjugation Technology Platforms

13. Assesment Of Non-Clinical Data, First In Human Dosing

14. Patent Analysis

15. Case Study: ADC Manufacturing

16. Market Forecast And Opportunity Analysis

17. SWOT Analysis

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List Of Companies And Organizations

• 3P Biopharmaceuticals
• 3SBio
• 5AM Ventures
• Aarhus University Hospital
• Abbott
• AbbVie
• AbbVie Contract Manufacturing
• AbGenomics
• ABL Bio
• Abraxis BioScience
• Abzena
• Academic and Community Cancer Research United (ACCRU)
• Academisch Medisch Centrum (AMC)
• Academy of Military Medical Sciences
• ACES Pharma
• Acute Leukemia French Association (ALFA)
• ADC Biotechnology
• ADC Therapeutics
• Adimab
• Advanced Biotechnologies Venture Fund
• Advanced Proteome Therapeutics Corporation
• Advantage Capital
• Advent Venture Partners
• Affimed
• Affinity Life Sciences
• Agensys
• Aichi Cancer Center Hospital
• AIDS Malignancy Consortium (AMC)
• Ajinomoto Althea
• Alcami
• Alexandria Real Estate Equities
• Alligator Bioscience
• Allos Therapeutics
• Allozyne
• Ally Bridge Group
• Almac Group
• Alnylam Pharmaceuticals
• Alta Partners
• Alteogen
• Ambrx
• Amgen
• Amgen Ventures
• AMRI
• Angiex
• Apax Partners
• APO-T
• Apposite Capital
• Apricot Capital
• Aravis Ventures
• ARCH Venture Partners
• Array BioPharma
• Arrowpoint Partners
• Asan Medical Center
• Asana BioSciences
• Ash Stevens
• Aspyrian Therapeutics
• Astellas Pharma
• AstraZeneca
• Asymchem
• Auven Therapeutics
• Avacta
• Avicenna Oncology
• AvidBiologics
• BankInvest Group
• Barbara Ann Karmanos Cancer Institute
• Baxter BioPharma Solutions
• Bayer HealthCare
• Baylor College of Medicine
• BDC Capital
• Bear Stearns Health Innoventures
• Beatson West of Scotland Cancer Centre
• Beckman Research Institute of City of Hope
• BeiGene
• Beijing Cancer Hospital
• BerGenBio
• Bicycle Therapeutics
• BioAgilytix
• BioAtla
• Biogen
• BioGeneration Ventures
• BioMed Valley Discoveries
• BioOutsource
• Bio-Synthesis
• BioTechnique
• Biotecnol
• Biotest
• BlinkBio
• Boehringer Ingelheim
• Boehringer Ingelheim Venture Fund
• BOM Capital
• Bregua Corporation
• Brigham and Women's Hospital
• Bristol-Myers Squibb (BMS)
• Brown University
• BSP Pharmaceuticals
• BZL Biologics
• California Institute for Regenerative Medicine (CIRM)
• Cambrex
• Cancer Research UK Centre for Drug Development
• Cancer Treatment Centers of America
• Cantonal Hospital St. Gallen
• CARBOGEN AMCIS
• CARB-X
• Carnegie Kapitalforvaltning
• Cascade Investment Group
• Cascadian Therapeutics
• Casdin Capital
• Catalent
• Catalent Biologics
• Catapult Ventures
• CEL Healthcare Fund
• Celgene
• Celldex Therapeutics
• Cellectar Biosciences
• Cellerant Therapeutics
• Centocor Ortho Biotech Services
• Centre Hospitalier Lyon Sud
• Centre Oscar Lambret
• Centrose
• Cerbios-Pharma
• ChemCon
• ChemPartner
• Children's Hospital Los Angeles (CHLA)
• Children's Hospital of Philadelphia (CHOP)
• Children's Mercy Hospital
• Children's Oncology Group (COG)
• Chinese Academy of Medical Sciences
• Chiron Pharmaceuticals
• CHU de Limoges
• Chugai Pharmaceuticals
• Churchill Hospital
• CMC Biologics
• COARE Biotechnology
• Columbia University
• Comprehensive Cancer Center City of Hope
• Compugen
• Concortis Biotherapeutics
• Cormorant Asset Management
• Cornell University
• Creative Biolabs
• Credit Suisse First Boston Next Fund
• Crescendo Biologics
• Crocker Ventures
• CTI Life Sciences Fund
• Cytogen
• CytomX Therapeutics
• Cytovance Biologics
• Daiichi Sankyo
• Dalton Pharma Services
• Dana-Farber Cancer Institute
• Dansk Erhvervsinvestering
• Debiopharm
• Deerfield Management
• Division of Rheumatology, Michigan Medicine
• Dophen Biomed
• Dow Employees' Pension Plan
• Dow Venture Capital
• Duke University
• Duquesne Capital Management
• ECOG-ACRIN Cancer Research Group
• EirGenix
• Eisai
• Elder Pharmaceuticals
• Eleven Biotherapeutics
• Eli Lilly
• Endo Pharmaceuticals
• Esperance Pharmaceuticals
• ETH Zurich
• Eucodis Bioscience
• Evonik
• Expansion Venture Capital
• Extend Biopharma
• Fabrus
• Ferring Pharmaceuticals
• Ferro Pfanstiehl Laboratories
• Fidelity Management & Research Company
• Fonds de solidarit FTQ
• Formation Biologics
• Formosa Laboratories
• For-Robin
• Fortis Therapeutics
• Fosun Pharma
• Fox Chase Cancer Center
• Fred Alger Management
• Fred Hutchinson Cancer Research Center
• Freeman Hospital
• FUJIFILM Diosynth Biotechnologies
• Genentech
• Genmab
• Genzyme
• German Hodgkin Study Group
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Global Bio-Chem
• Glykos
• Glynn Capital
• Glythera
• Goodwin Biotechnology
• GTC Biotherapeutics
• Guardant Health
• Guy's and St. Thomas' NHS Foundation Trust
• H. Lee Moffitt Cancer Center & Research Institute
• Halozyme
• Hambrecht & Quist Capital Management
• Hangzhou DAC Biotech
• Hartmann Oncology Radiotherapy Group
• HBM Healthcare Investments
• HBM Partners
• HealthCap
• Heidelberg Pharma
• Heraeus Precious Metals
• Hercules Capital
• HNI Corporation
• Hpital Necker-Enfants Malades
• HOPU Investment Management
• Hospital Clinic of Barcelona
• Hospital General de Valencia
• Hospital La Fe
• Hospital St. Louis
• Hospital Universitario de Salamanca
• Houston Methodist Cancer Center
• Houston Methodist Hospital
• Humanwell Healthcare
• iBIOSOURCE
• IDT Australia
• IDT Biologika
• Igenica Biotherapeutics
• ImClone Systems
• Immatics
• ImmunoGen
• Immunomedics
• INC Research
• Index Ventures
• Indiana University School of Medicine
• Indiana University Simon Cancer Center
• Innate Pharma
• Innovate UK
• Innovis Investments
• Institut Bergoni
• Institut Curie - Hpital Ren Hugenin
• Institut de Cancrologie de Lorraine (ICL)
• Institut Jules Bordet
• International Biotechnology Trust
• International College of Manitoba (ICM)
• Invenra
• IONTAS
• IRCCS AOU San Martino
• Iroquois Capital Group
• Istituto di Ematologia di Bologna
• IU Health Goshen Center for Cancer Care
• JAFCO
• Janssen Biotech
• Jennison Associates
• Johns Hopkins University
• Johnson & Johnson
• Jonsson Comprehensive Cancer Center
• Kairos Therapeutics
• Kaplan Medical Center
• Karmanos Cancer Institute
• Karolinska University Hospital
• Kemwell Biopharma
• Kolltan Pharmaceuticals
• Korea Cancer Center Hospital
• Kumamoto University Hospital
• Kyowa Hakko Kirin
• Lead Discovery Center
• LegoChem Biosciences
• Lehigh University
• Leica Biosystems
• Ligand Pharmaceuticals
• Lilly Ventures
• LinXis
• LODH Private Equity
• Lombard Odier
• Lonza
• Loyola University
• Lumira Capital
• Lymphoma Study Association (LYSA)
• MAB Discovery
• MabPlex
• MabSpace Biosciences
• MabVax Therapeutics
• MacroGenics
• Masonic Cancer Center
• Massachusetts General Hospital
• Massey Cancer Center
• Maverick Capital
• Max Planck Innovation
• Mayo Clinic
• MD Anderson Cancer Center
• Medarex
• MediaPharma
• Medical College of Wisconsin
• MedImmune
• Meditope Biosciences
• Medivation
• MedStar Washington Hospital Center
• Memorial Sloan Kettering Cancer Center
• Menarini Group
• Merck Serono
• Merrimack Pharmaceuticals
• Mersana Therapeutics
• Millennium Pharmaceuticals
• MImAbs
• Minomic
• Mitsubishi Tanabe Pharma
• Modal Capital Partners
• Morphotek
• MPM Capital
• MS Seed Capital
• MS Ventures
• MultiCell Immunotherapeutics
• Nantes University Hospital
• Natco Pharma
• National Cancer Center of Korea
• National Cancer Institute
• National Research Council of Canada
• NBE Therapeutics
• Nerviano Medical Sciences
• New Enterprise Associates
• New York Medical College
• Nextech Venture
• Noonday Asset Management
• Nordic Nanovector
• Norfolk and Norwich University Hospital
• Northeast Securities Prosperity Healthcare Fund
• Northwestern University
• Novartis
• Novartis Venture Fund
• Novasep
• Novella Clinical
• Novimmune
• NSABP Foundation
• OBI Pharma
• OGD2 Pharma
• Ohio State University
• Oncology Institute of Southern Switzerland
• Oncotec Pharma Produktion
• Onyx Pharmaceuticals
• OPKO Health
• OrbiMed Advisors
• OrbiMed Associates
• Oregon Health and Science University
• Orphan Medical
• Osage University Partners
• Oslo University Hospital
• OVP Venture Partners
• Oxford BioTherapeutics
• Oxford Capital Partners
• Oxford Finance
• Oxis Biotech
• Pacific GMP
• Particle Sciences
• Patheon
• Perceptive Advisors
• PETHEMA Foundation
• Pfizer
• Pfizer Venture Investments
• Pharmacyclics
• PharmaMar
• Philochem
• Philogen
• Pierre Fabre
• Piramal Pharma Solutions
• Policlinico S. Orsola-Malpighi
• PolyTherics
• PrECOG
• Presidio Partners
• Princess Margaret Hospital
• ProBioGen
• Progenics Pharmaceuticals
• ProJect Pharmaceutics
• ProLynx
• PSI Company
• Purdue University
• QPS Holdings
• Quanta BioDesign
• Queen Elizabeth Hospital
• Ramot
• Recepta Biopharma
• Redmile Group
• Redwood Bioscience
• Redwood Pharma
• Regeneron Pharmaceuticals
• Regional Center for the Fight Against Cancer
• RemeGen
• ReqMed Company
• Research Corporation Technologies
• Roche
• Roche Venture Fund
• Rock Springs Capital Management
• Roswell Park Cancer Institute
• Royal Hospital for Children Glasgow
• Royal Liverpool Hospital
• Samsung Medical Center
• Sandoz
• Sanofi-Aventis
• Sapienza University of Rome
• Sapporo Medical University
• Sarah Cannon Research Institute
• Scale Venture Partners
• Schering-Plough
• SCIEX
• Scottish Widows Investment Partnership
• SCRI Innovations
• SEASUN BIOMATERIALS
• Seattle Cancer Care Alliance
• Seattle Genetics
• Seoul National University Hospital
• Serina Therapeutics
• Severance Hospital
• Shanghai Fosun Pharmaceutical
• Shanghai Rui Jin Hospital
• Shenogen
• Sigma-Aldrich
• Silicon Valley Bank
• Sinopharm Capital
• Skyline Ventures
• Societa Italiana Corticosteroidi
• Sofinnova Ventures
• Sorenson Development
• Sorrento Therapeutics
• SOTIO
• South East Growth Fund & Management
• Southampton General Hospital
• Southwest Oncology Group
• Spectrum Pharmaceuticals
• Spirogen
• SR One
• St James University Hospital
• St. Catherine of Siena Medical Center
• St. Joseph's Health Care
• St. Jude Children's Research Hospital
• Stanford University
• State University of New York
• Stemcentrx
• SUEZ Ventures
• Sutro Biopharma
• SV Life Sciences
• Symbiosis Pharmaceutical Services
• Symphogen
• Synaffix
• Syndivia
• Syngene
• Syntarga
• Synthon
• Synthon Biopharmaceuticals
• Synthorx
• Tagworks Pharmaceuticals
• Takeda Oncology
• Takeda Pharmaceutical
• Tavistock Life Sciences
• Tekla Healthcare Investors
• Tekla Life Science Investors
• The Chemistry Research Solution
• The Christie NHS Foundation Hospital
• The Cleveland Clinic
• The Column Group
• The Royal Marsden NHS Foundation Trust
• The Scripps Research Institute
• The Scripps Research Institute
• The Wild Family Office
• Themelios Ventures Partners
• Theranyx
• Thiel Capital
• ThioLogics
• Third Rock Ventures
• TPG-Axon Capital
• Triphase Accelerator
• Tube Pharmaceuticals
• Tubulis Technologies
• Tulane University
• Twilight Venture Partners
• UNC Lineberger Comprehensive Cancer Center
• Unilever Technology Ventures
• Union Carbide Employees' Pension Plan
• United Therapeutics
• Universitair Medisch Centrum
• Universitair Ziekenhuizen Leuven
• University Hospital Bern
• University Hospital Dresden
• University Hospital of Udine
• University Hospital of Wales
• University Hospital Ramon y Cajal
• University Hospitals Seidman Cancer Center
• University of Alabama
• University of Arizona
• University of California
• University of Cologne
• University of Copenhagen
• University of Georgia
• University of Kansas Medical Center Research Institute
• University of Miami
• University of Minnesota
• University of Munich
• University of New Mexico Cancer Center
• University of Nottingham
• University of Oklahoma Stephenson Cancer Center
• University of Pennsylvania Abramson Cancer Center (ACC)
• University of Pittsburgh
• University of Rochester Medical Center
• University of Texas Health Science Center
• University of Ulm
• University of Washington Cancer Consortium
• University of Western Ontario
• US Oncology Research
• UT Southwestern Medical Center
• Valeant Pharmaceuticals
• Vanderbilt-Ingram Cancer Center
• Venrock Healthcare Capital Partners
• Ventana Medical Systems
• Venture Associates
• Venture West
• Ventures West
• Versailles Hospital
• Versant Ventures
• Vertex Ventures
• Victor Hugo Surgical Clinic
• Virginia Cancer Specialists
• Visterra
• VivaMab
• Vivo Capital
• VLG Investments
• VU University Medical Center Amsterdam
• Vulcan Capital
• Wake Forest University Health Sciences
• Washington University School of Medicine
• Waters Corporation
• Watson Pharmaceuticals
• Weill Medical College of Cornell University
• Wellington Management Company
• Western Regional Medical Center
• Wharton Biotechnology Partners
• WILEX
• Wilmot Cancer Institute
• Wntrix
• WT Investment Advisors Fund
• WuXi AppTec
• Wyeth
• Xencor
• Xintela
• Yale University
• Yuhan Corporation
• Zhejiang Medicine
• Ziff Asset Management
• Zymeworks
• ZymoGenetics

For more information about this report visit https://www.researchandmarkets.com/research/xwq5lt/antibody_drug

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Oncology Drugs